Author

J. M. Krill-Burger

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Assay:CRISPR screen· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

F. Vazquez· 3 shared B. R. Paolella· 2 shared D. E. Root· 2 shared J. M. McFarland· 2 shared J. S. Boehm· 2 shared T. R. Golub· 2 shared A. A. Borah· 1 shared A. Asfaw· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 35 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. Vazquez

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal

J. M. Krill-Burger, J. M. Dempster, A. A. Borah, B. R. Paolella, D. E. Root, T. R. Golub, J. S. Boehm, W. Hahn, J. M. McFarland, F. Vazquez, A. Tsherniak

This study compares CRISPR-Cas9 and RNAi screens to identify cancer vulnerabilities, finding that RNAi better detects pan-dependencies while CRISPR identifies more dependencies overall.

bioRxiv · Mar 2, 2022Cancer Biology

A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Anti-apoptotic Protein in Kidney Cancer

T. M. Grubb, S. Maganti, J. M. Krill-Burger, C. Fraser, L. Stransky, T. Radivoyevitch, K. Sarosiek, F. Vazquez, W. G. Kaelin, A. Chakraborty

The paper identifies a mesenchymal tumor cell state that increases dependency on BCL-XL in kidney cancer, showing anti-tumor efficacy of a BCL-XL inhibitor.

bioRxiv · Jan 29, 2022 · PreprintCancer Biology

Phosphate dysregulation via the XPR1:KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer

D. P. Bondeson, B. R. Paolella, A. Asfaw, M. Rothberg, T. Skipper, C. Langan, A. Gonzalez, L. Surface, K. Ito, M. Kazachkova, W. N. Colgan, A. Warren, J. Dempster, J. M. Krill-Burger, M. Ericcson, , T. R. Golub

The paper identifies XPR1 and KIDINS220 as therapeutic targets in ovarian cancer by showing their role in phosphate dysregulation leading to cell death.

bioRxiv · Oct 16, 2020Cancer Biology